Results 121 to 130 of about 2,716,407 (409)

Immune-Mediated Cytotoxicity in Inflammatory Bowel Disease

open access: yesCanadian Journal of Gastroenterology, 1990
Thirty years of research on the role of immune-mediated cytotoxic activity in the tissue injury of inflammatory bowel disease (IBD) has yielded only inconclusive data on the relevance of cytotoxic mechanisms. Two hypotheses have been advanced.
Stephan R Targan   +2 more
doaj   +1 more source

Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells

open access: yesJournal of Experimental Medicine, 2003
Currently most attempts at cancer immunotherapy involve the generation of CD8+ cytotoxic T lymphocytes (CTLs) against tumor-associated antigens. Many tumors, however, have been immunoselected to evade recognition by CTLs and thus alternative approaches ...
J. Mattes   +6 more
semanticscholar   +1 more source

Interleukin-10 containing normal human serum inhibits granzyme B release but not perforin release from alloreactive and EBV-specific T cell clones [PDF]

open access: yes, 2007
Interleukin-10 (IL-10), also known as cytokine synthesis inhibitory factor, has pleiotropic effects in immunoregulation and inflammation. It is capable of inhibiting synthesis of pro-inflammatory cytokines like interferon γ (IFNγ), IL-2, IL-3,
Hideya Sato   +4 more
core   +2 more sources

Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80(dim), CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients [PDF]

open access: yes, 1996
We have shown previously that granulocyte-macrophage colony-stimulating factor-stimulated mouse bone marrow-derived MHC class II+ dendritic cell (DC) progenitors that are deficient in cell surface expression of the costimulatory molecules B7-1 (CD8O) and
Angus W. Thomson   +48 more
core   +1 more source

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

open access: yesMolecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva   +5 more
wiley   +1 more source

Cytotoxic T cells: Lyt phenotype and blocking of killing activity by Lyt antisera [PDF]

open access: green, 1979
Eiichi Nakayama   +4 more
openalex   +1 more source

Long-term culture of human antigen-specific cytotoxic T-cell lines

open access: yesJournal of Experimental Medicine, 1978
Long-term cultures of human cytotoxic T-cell lines (H-CTLL) were established. H-CTLL cells were strictly dependent on growth upon a T- cell growth factor (TCGF) produced by phytohemagglutinin-stimulated normal human peripheral blood lymphocytes.
S. Gillis   +3 more
semanticscholar   +1 more source

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

open access: yesMolecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková   +14 more
wiley   +1 more source

Association of high‐dose radioactive iodine therapy with PPM1D‐mutated clonal hematopoiesis in older individuals

open access: yesMolecular Oncology, EarlyView.
In thyroid cancer patients, high‐dose (≥7.4 GBq) radioactive iodine therapy (RAIT) was associated with a higher prevalence of clonal hematopoiesis (variant allele frequency >2%) in individuals aged ≥50 years (OR = 2.44). In silico analyses showed that truncating PPM1D mutations conferred a selective advantage under these conditions.
Jaeryuk Kim   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy